Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital or Acquired Haemophilia and Other Congenital Bleeding Disorders

Author： Siddiqui M. Asif A.   Scott Lesley J.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.65, Iss.8, 2005-01, pp. : 1161-1177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX

By Lyseng-Williamson Katherine A.   Plosker Greg L.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1007-1029

Adis International

Access to resources Recommend Favorite

Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®): A Review of its Use in the Management of Patients with Haemophilia A

By Dhillon Sohita  

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 987-1007

Adis International

Access to resources Recommend Favorite

Eptacog alfa [recombinant factor VIIa] reduces perioperative blood loss in patients undergoing retropubic prostatectomy

By  

Inpharma, Vol. 1, Iss. 1371, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

By  

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The use of eptacog-α [recombinant factor VIIa] to treat acute intracerebral haemorrhage (ICH) may be highly cost effective in the UK

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite